Myomo shares surge 10.12% after-hours after reporting record Q3 revenues, 229 orders, and $20.1M cash boost from new financing.

Myomo Inc. surged 10.12% in after-hours trading following the release of its third-quarter 2025 financial results, which highlighted record U.S. and international orthotics and prosthetics revenues, 229 MyoPro orders (the highest of the year), and a 10% year-over-year revenue increase to $10.1 million. The company reiterated its full-year revenue guidance of $40–$42 million, citing strong sequential cost reductions, a 5% decline in cost per pipeline add, and the successful launch of the MyoConnect program to drive recurring patient referrals. Additionally, a new $17.5 million debt facility strengthened liquidity, with pro forma cash balances reaching $20.1 million. These operational improvements, coupled with robust order growth and strategic cost efficiencies, fueled investor optimism about Myomo’s near-term prospects and operating leverage.